Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 23;14(7):2188.
doi: 10.3390/jcm14072188.

Male Hormonal Contraception-Current Stage of Knowledge

Affiliations
Review

Male Hormonal Contraception-Current Stage of Knowledge

Julia Bania et al. J Clin Med. .

Abstract

Male hormonal contraception has been the focus of extensive research efforts aimed at identifying effective and reversible methods for male fertility control. This review summarizes the current state of knowledge, key achievements, and future directions in the development of male hormonal contraception. A review was conducted using the PubMed, Embase, and Scopus databases. The search strategy included terms such as "male hormonal contraception", "Nestorone", "7α,11β-Dimethyl-19-nortestosterone 17β-undecanoate (DMAU)" and "11β-methyl-19-nortestosterone 17β-dodecylcarbonate (11β-MNTDC)". A total of 107 references were analyzed to synthesize the most relevant findings regarding the hormonal contraceptive agents under investigation. The review outlines historical and recent advancements in male hormonal contraception, highlighting compounds that have demonstrated limitations in effectiveness, side effects, or inconvenient administration. Notable candidates under study include 7α-methyl-19-nortestosterone (MENT), DMAU, 11β-MNTDC, and the combination of segesterone acetate with testosterone in gel form. These agents show promise due to their ability to suppress follicle-stimulating hormone (FSH) and luteinizing hormone (LH), leading to effective spermatogenesis inhibition with minimal side effects. Additionally, the phenomenon of spermatogenic rebound is considered. Among the investigated agents, oral DMAU, 11β-MNTDC, and the Nestorone-testosterone gel appear to be the most promising candidates for male hormonal contraception due to their high efficacy, user-friendly administration, and favorable safety profiles. However, further large-scale clinical trials are necessary to confirm their long-term effects on human health and fertility, ensuring their viability as future contraceptive options.

Keywords: 11β-MNTDC; DMAU; MENT; Nestorone; contraception; male contraception; male hormonal contraception; spermatogenesis; spermatogenic rebound.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The feedback loop of male sex hormones is illustrated. They are crucial in the process of spermatogenesis. Tropic hormones are marked in purple, hormones produced within the testes are marked in yellow, and substances investigated for male hormonal contraception are marked in green. Arrows with the shape of circles with a rectangle in the center indicate an inhibitory effect, while arrows without this shape signify the stimulation. The figure also depicts the target sites of action for compounds studied as potential male hormonal contraceptives. DMAU—7α,11β-dimethyl-19-nortestosterone 17β-undecanoate, 11β-MNTDC—11β-methyl-19-nortestosterone 17β-dodecylcarbonate, MENT—7α-methyl-19-nortestosterone, LH—luteinizing hormone, FSH—follicle-stimulating hormone, GnRH—gonadotropin-releasing hormone.

Similar articles

References

    1. Reynolds-Wright J.J., Cameron N.J., Anderson R.A. Will Men Use Novel Male Contraceptive Methods and Will Women Trust Them? A Systematic Review. J. Sex. Res. 2021;58:838–849. doi: 10.1080/00224499.2021.1905764. - DOI - PubMed
    1. Nguyen B.T., Jacobsohn T.L. Men’s willingness to use novel male contraception is linked to gender-equitable attitudes: Results from an exploratory online survey. Contraception. 2023;123:110001. doi: 10.1016/j.contraception.2023.110001. - DOI - PubMed
    1. Campelia G.D., Abbe C., Nickels L.M., McElmeel E., Amory J.K. ‘Shared risk’: Reframing risk analysis in the ethics of novel male contraceptives. Contraception. 2020;102:67–69. doi: 10.1016/j.contraception.2020.05.014. - DOI - PMC - PubMed
    1. Thirumalai A., Amory J.K. Emerging approaches to male contraception. Fertil. Steril. 2021;115:1369–1376. doi: 10.1016/j.fertnstert.2021.03.047. - DOI - PMC - PubMed
    1. Haakenstad A., Angelino O., Irvine C.M.S., Bhutta Z.A., Bienhoff K., Bintz C., Causey K., Ashworth Dirac M., Fullman N., Gakidou E., et al. Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400:295–327. doi: 10.1016/S0140-6736(22)00936-9. - DOI - PMC - PubMed

LinkOut - more resources